Showing results (51-60 of 237) with videos related to

Sort By:
Pageof 24
Genes|December 24, 2021
Iron Deficiency Caused by Intestinal Iron Loss-Novel Candidate Genes for Severe AnemiaCarolina Huettmann, Matthias Stelljes, Sugirthan Sivalingam, et al.
Leukemia & Lymphoma|March 29, 2021
Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancyDaniela V Wenge, Klaus Wethmar, Jan-Henrik Mikesch, et al.
Blood Cancer Journal|November 20, 2019
Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMTAvichai Shimoni, Myriam Labopin, Jürgen Finke, et al.
Transplantation and Cellular Therapy|May 9, 2021
Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationAndreas Rank, Christophe Peczynski, Myriam Labopin, et al.
Transplantation|February 14, 2007
Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effectsMatthias Stelljes, Christiane Specht, Jörn Albring, et al.
Blood|April 20, 2004
Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targetsMatthias Stelljes, Robert Strothotte, Hans-Gerd Pauels, et al.
Cancer|February 18, 2017
Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMTJiří Pavlů, Myriam Labopin, Anna K Zoellner, et al.
Transplantation and Cellular Therapy|March 9, 2025
Outcome of Patients With IDH-Mutated AML Following Allogeneic Stem Cell Transplantation-A Retrospective Analysis on Behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRSTThomas Schroeder, Sarah Flossdorf, Claudia Schuh, et al.
Cancer|March 29, 2019
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Blood Cancer Journal|August 10, 2020
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burdenDaniel J DeAngelo, Anjali S Advani, David I Marks, et al.
Pageof 24